Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Eva Fortea Verdejo is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/25/2025
Buy Now | Get Alert | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
04/17/2025 | BCAX | Buy Now | Bicara Therapeutics | $14.54 | -44.98% | Eva Fortea Verdejo30% | → $8 | Initiates | → Underweight | Get Alert |
03/06/2025 | ITOS | Buy Now | ITeos Therapeutics | $7.35 | 131.29% | Eva Fortea Verdejo30% | $19 → $17 | Maintains | Overweight | Get Alert |
02/28/2025 | XNCR | Buy Now | Xencor | $10.51 | 213.99% | Eva Fortea Verdejo30% | $37 → $33 | Maintains | Overweight | Get Alert |
12/19/2024 | ITOS | Buy Now | ITeos Therapeutics | $7.35 | 158.5% | Eva Fortea Verdejo30% | $31 → $19 | Maintains | Overweight | Get Alert |
12/12/2024 | XNCR | Buy Now | Xencor | $10.51 | 252.05% | Eva Fortea Verdejo30% | → $37 | Initiates | → Overweight | Get Alert |
10/08/2024 | RCUS | Buy Now | Arcus Biosciences | $8.30 | 249.4% | Eva Fortea Verdejo30% | → $29 | Initiates | → Overweight | Get Alert |
08/13/2024 | ITOS | Buy Now | ITeos Therapeutics | $7.35 | 321.77% | Eva Fortea Verdejo30% | → $31 | Initiates | → Overweight | Get Alert |
05/03/2024 | KNSA | Buy Now | Kiniksa Pharmaceuticals | $21.64 | 57.12% | Eva Fortea Verdejo30% | → $34 | Initiates | → Overweight | Get Alert |